Bifogade filer
Kurs
-8,30%
Likviditet
0,13 MSEK
Kalender
Est. tid* | ||
2025-11-25 | 05:00 | Kvartalsrapport 2025-Q3 |
2025-08-26 | 05:00 | Kvartalsrapport 2025-Q2 |
2025-06-23 | - | Årsstämma |
2025-05-23 | - | Kvartalsrapport 2025-Q1 |
2025-05-02 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
2025-02-27 | - | Bokslutskommuniké 2024 |
2024-11-14 | - | Kvartalsrapport 2024-Q3 |
2024-08-26 | - | Kvartalsrapport 2024-Q2 |
2024-05-13 | - | Kvartalsrapport 2024-Q1 |
2024-04-26 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
2024-04-25 | - | Årsstämma |
2024-02-27 | - | Bokslutskommuniké 2023 |
2023-11-14 | - | Kvartalsrapport 2023-Q3 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-05-25 | - | Kvartalsrapport 2023-Q1 |
2023-05-19 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
2023-05-17 | - | Årsstämma |
2023-02-24 | - | Bokslutskommuniké 2022 |
2022-11-14 | - | Kvartalsrapport 2022-Q3 |
2022-08-27 | - | Kvartalsrapport 2022-Q2 |
2022-05-27 | - | Kvartalsrapport 2022-Q1 |
2022-04-11 | - | Extra Bolagsstämma 2022 |
2022-04-08 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
2022-04-07 | - | Årsstämma |
2022-02-25 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-27 | - | Kvartalsrapport 2021-Q2 |
2021-04-21 | - | Årsstämma |
2021-04-21 | - | Kvartalsrapport 2021-Q1 |
2021-04-08 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-11-23 | - | Kvartalsrapport 2020-Q3 |
2020-09-07 | - | Extra Bolagsstämma 2020 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-06-12 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
2020-06-11 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-21 | - | Bokslutskommuniké 2019 |
2019-11-25 | - | Kvartalsrapport 2019-Q3 |
2019-08-27 | - | Kvartalsrapport 2019-Q2 |
2019-05-07 | - | Kvartalsrapport 2019-Q1 |
2019-04-09 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
2019-04-08 | - | Årsstämma |
2018-11-13 | - | Kvartalsrapport 2018-Q3 |
2018-08-27 | - | Kvartalsrapport 2018-Q2 |
2018-05-07 | - | Kvartalsrapport 2018-Q1 |
2018-04-10 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
2018-04-09 | - | Årsstämma |
2018-02-23 | - | Bokslutskommuniké 2017 |
2017-08-25 | - | Kvartalsrapport 2017-Q2 |
2017-05-09 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
2017-05-08 | - | Årsstämma |
2017-05-05 | - | Kvartalsrapport 2017-Q1 |
2017-02-20 | - | Bokslutskommuniké 2016 |
2016-11-11 | - | Kvartalsrapport 2016-Q3 |
2016-08-26 | - | Kvartalsrapport 2016-Q2 |
2016-05-10 | - | X-dag ordinarie utdelning DBP B 0.00 SEK |
2016-05-09 | - | Årsstämma |
2016-05-04 | - | Kvartalsrapport 2016-Q1 |
2016-02-19 | - | Bokslutskommuniké 2015 |
2015-10-23 | - | Kvartalsrapport 2015-Q3 |
2015-08-14 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Bioteknik |
Double Bond Pharmaceutical International AB (publ) ("DBP") has signed a 3-way agreement with Bio Vitos Medical Ltd ("Bio Vitos") and Academpharm (Republic of Belarus) concerning a technical and scientific collaboration.
The purpose of the agreement between Academpharm and Bio Vitos is to get access to its products on the markets in the Eurasian Economic Union (EaEU). Bio Vitos has a line of more than 40 Omega 3 products from North Norway, containing vitamins, minerals, iron succinate etc.
The Bio Vitos agreement with Academpharm, gives access to the countries: Belarus, Russia, Kazakhstan, Turkmenistan, Azerbaijan, and Armenia, a total of markets with almost 200 million inhabitants.
As previously announced, DBP owns 20 % of Bio Vitos: https://mb.cision.com/Main/12720/3440256/1486281.pdf
About BioVitos: BioVitos is an English limited company, specializing in development and sale of dietary supplements, based on high quality Omega 3 salmon oil from North Norway.
Bio Vitos also has Omega 3 products added with cannabis oil (CBD).
Bio Vitos is in preparation for an application to be part of the Danish Medical Agency's pilot program for medical cannabis.
29.39 % of Bio Vitos is owned by Craven House Capital Plc ("CRV") which is listed on the London Stock Exchange's AIM list.
About Academpharm: Academpharm is a dynamically developing high-tech state-owned pharmaceutical company for production and distribution of high-quality drug substances and biologically active additives.
Belarus State Academpharm is focused on the pharmaceutical industry within the Eurasian Economic Union (EaEU), the European Union (EU) and the US market. https://academpharm.by/en/